Guggenheim analyst Vamil Divan raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $115 from $114 and keeps a Buy rating on the shares. The firm is updating its model after the company reported “yet another beat and raise quarter” and following its follow-up conversation with management.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals’ Earnings Call Highlights Record Growth
- ANI Pharmaceuticals Reports Record Q3 2025 Results
- ANI Pharmaceuticals: Strong Commercial Execution and Promising Growth Prospects Reinforce Buy Rating
- ANI Pharmaceuticals raises FY25 adj. EPS view to $7.37-$7.64 from $6.98-$7.35
- ANI Pharmaceuticals reports Q3 adjusted EPS $2.04, consensus $1.77